In this week's Homerun Slides, FDA-approved GLP-1s and GLP-1s in development.

Cause of NAFLD: physical inactivity: Although physical training predominantly enhances muscle insulin sensitivity, cross-sectional epidemiologic data and studies on effects of physical training suggest that exercise may decrease liver fat even in the face of unchanged body weight [50]. In a cross-sectional study in 72,359 healthy Korean adults, subjects who were exercising regularly had a 28–53% lower risk of NAFLD across almost all BMI deciles.

A few years ago I served as president of the Tampa Bay chapter of JDRF. At the same time one of my good Pharmacist-CDE friends was president of the local ADA chapter, and we would always tease each other as to who was raising the most money for our respective …

Study finds diabetes complications and mortality may be better predicted with elevated 1-hour blood glucose levels compared with 2-hour blood glucose levels.

Congress creates abbreviated licensure pathway for biological products similar to or interchangeable with FDA-approved products.

Severe hypoglycemia in type 2 diabetes was found to be associated with increased cardiac failure and mortality.

Diastolic function begins to decline in early stages of type 2 diabetes.

Insulin found to provide better control of post-prandial glucose without significantly elevating hypoglycemia risk.

Do you believe that glucose monitors will be a thing of the past as continuous glucose monitors (CGM) become less expensive and more accurate? Follow the link to see how you and your colleagues compare!

A 54-year-old male presents to your office for an initial visit. His past medical history is significant for hypertension, hypertriglyceridemia and acute pancreatitis. His current lab results show an A1C 9.1%, which is confirmed on a repeat lab. You would like to start him on an antihyperglycemic treatment regimen. Which of the following two-drug combinations is contraindicated for this patient? A. Metformin + a sulfonylurea B. Metformin + an insulin C. Metformin + a meglitinide D. Metformin + a GLP-1 receptor agonist Follow the link to get the answer.